SINOPHARM’s Subsidiary CNMDC Posts 1.23% Revenue Growth but 20.41% Profit Slide in Q1 2026

Bulletin Express04-23

Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three months ended 31 March 2026.

Revenue and Profitability • Revenue edged up to RMB 17.00 billion, a 1.23% year-on-year increase from RMB 16.79 billion. • Operating profit fell to RMB 220.19 million, down 20.41% from RMB 276.67 million, reflecting margin pressure. • Total comprehensive income attributable to the parent slipped 7.47% to RMB 115.15 million versus RMB 124.44 million a year earlier.

Cash Flow • Net cash used in operating activities widened to an outflow of RMB 4.57 billion, compared with a RMB 3.13 billion outflow in the prior-year period, marking a 45.86% deterioration.

Balance Sheet Position • Total assets grew 3.82% quarter-to-date to RMB 59.49 billion, up from RMB 57.30 billion at the start of the period. • Equity attributable to the parent increased 1.39% to RMB 8.42 billion from RMB 8.30 billion.

Key Takeaways CNMDC delivered modest top-line growth in the first quarter of 2026, yet faced notable declines in operating profit and net income amid a sharper operating cash outflow. Asset expansion outpaced growth in shareholder equity, underscoring a need to monitor leverage and cash-generation trends in subsequent quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193178557?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193178557","market":"hk","top_or_hot":-1,"title":"SINOPHARM’s Subsidiary CNMDC Posts 1.23% Revenue Growth but 20.41% Profit Slide in Q1 2026","media":"Bulletin Express","content":"<p>Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three months ended 31 March 2026.</p>\n<p>Revenue and Profitability  \n• Revenue edged up to RMB 17.00 billion, a 1.23% year-on-year increase from RMB 16.79 billion.  \n• Operating profit fell to RMB 220.19 million, down 20.41% from RMB 276.67 million, reflecting margin pressure.  \n• Total comprehensive income attributable to the parent slipped 7.47% to RMB 115.15 million versus RMB 124.44 million a year earlier.</p>\n<p>Cash Flow  \n• Net cash used in operating activities widened to an outflow of RMB 4.57 billion, compared with a RMB 3.13 billion outflow in the prior-year period, marking a 45.86% deterioration.</p>\n<p>Balance Sheet Position  \n• Total assets grew 3.82% quarter-to-date to RMB 59.49 billion, up from RMB 57.30 billion at the start of the period.  \n• Equity attributable to the parent increased 1.39% to RMB 8.42 billion from RMB 8.30 billion.</p>\n<p>Key Takeaways  \nCNMDC delivered modest top-line growth in the first quarter of 2026, yet faced notable declines in operating profit and net income amid a sharper operating cash outflow. Asset expansion outpaced growth in shareholder equity, underscoring a need to monitor leverage and cash-generation trends in subsequent quarters.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINOPHARM’s Subsidiary CNMDC Posts 1.23% Revenue Growth but 20.41% Profit Slide in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINOPHARM’s Subsidiary CNMDC Posts 1.23% Revenue Growth but 20.41% Profit Slide in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-23 17:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three months ended 31 March 2026.</p>\n<p>Revenue and Profitability  \n• Revenue edged up to RMB 17.00 billion, a 1.23% year-on-year increase from RMB 16.79 billion.  \n• Operating profit fell to RMB 220.19 million, down 20.41% from RMB 276.67 million, reflecting margin pressure.  \n• Total comprehensive income attributable to the parent slipped 7.47% to RMB 115.15 million versus RMB 124.44 million a year earlier.</p>\n<p>Cash Flow  \n• Net cash used in operating activities widened to an outflow of RMB 4.57 billion, compared with a RMB 3.13 billion outflow in the prior-year period, marking a 45.86% deterioration.</p>\n<p>Balance Sheet Position  \n• Total assets grew 3.82% quarter-to-date to RMB 59.49 billion, up from RMB 57.30 billion at the start of the period.  \n• Equity attributable to the parent increased 1.39% to RMB 8.42 billion from RMB 8.30 billion.</p>\n<p>Key Takeaways  \nCNMDC delivered modest top-line growth in the first quarter of 2026, yet faced notable declines in operating profit and net income amid a sharper operating cash outflow. Asset expansion outpaced growth in shareholder equity, underscoring a need to monitor leverage and cash-generation trends in subsequent quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"","article_id":"1193178557","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193178557","pubTimestamp":1776935376,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股"},"translate_title":"国药控股子公司CNMDC 2026年第一季度收入增长1.23%，但利润下滑20.41%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"Hong Kong, 23 Apr 2026 – Sinopharm Group Co. Ltd. (SINOPHARM) announced key unaudited figures for its medical-device subsidiary China National Medical Device Co., Ltd. (CNMDC) covering the three months ended 31 March 2026.\nRevenue and Profitability  \n• Revenue edged up to RMB 17.00 billion, a 1.23% year-on-year increase from RMB 16.79 billion.  \n• Operating profit fell to RMB 220.19 million, down 20.41% from RMB 276.67 million, reflecting margin pressure.  \n• Total comprehensive income attributable to the parent slipped 7.47% to RMB 115.15 million versus RMB 124.44 million a year earlier.\nCash Flow  \n• Net cash used in operating activities widened to an outflow of RMB 4.57 billion, compared with a RMB 3.13 billion outflow in the prior-year period, marking a 45.86% deterioration.\nBalance Sheet Position  \n• Total assets grew 3.82% quarter-to-date to RMB 59.49 billion, up from RMB 57.30 billion at the start of the period.  \n• Equity attributable to the parent increased 1.39% to RMB 8.42 billion from RMB 8.30 billion.\nKey Takeaways  \nCNMDC delivered modest top-line growth in the first quarter of 2026, yet faced notable declines in operating profit and net income amid a sharper operating cash outflow. Asset expansion outpaced growth in shareholder equity, underscoring a need to monitor leverage and cash-generation trends in subsequent quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193178557","isCrawlerRequest":true}